Now showing items 1-20 of 44

    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      <h4>Introduction</h4>Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual ...
    • The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. 

      Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; Strauss, DC; Fisher, C; Hayes, AJ; Judson, I; Thway, K; Jones, RL; Huang, PH (2019-10-10)
      The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ...
    • Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. 

      Wu, L; Shu, X; Bao, J; Guo, X; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia (2019-09)
      Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers ...
    • Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. 

      Girotti, MR; Gremel, G; Lee, R; Galvani, E; Rothwell, D; Viros, A; Mandal, AK; Lim, KHJ; Saturno, G; Furney, SJ; Baenke, F; Pedersen, M; Rogan, J; Swan, J; Smith, M; Fusi, A; Oudit, D; Dhomen, N; Brady, G; Lorigan, P; Dive, C; Marais, R (2016-03)
      <h4>Unlabelled</h4>Targeted therapies and immunotherapies have transformed melanoma care, extending median survival from ∼9 to over 25 months, but nevertheless most patients still die of their disease. The aim of precision ...
    • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. 

      Hamdi, Y; Soucy, P; Kuchenbaeker, KB; Pastinen, T; Droit, A; Lemaçon, A; Adlard, J; Aittomäki, K; Andrulis, IL; Arason, A; Arnold, N; Arun, BK; Azzollini, J; Bane, A; Barjhoux, L; Barrowdale, D; Benitez, J; Berthet, P; Blok, MJ; Bobolis, K; Bonadona, V; Bonanni, B; Bradbury, AR; Brewer, C; Buecher, B; Buys, SS; Caligo, MA; Chiquette, J; Chung, WK; Claes, KBM; Daly, MB; Damiola, F; Davidson, R; De la Hoya, M; De Leeneer, K; Diez, O; Ding, YC; Dolcetti, R; Domchek, SM; Dorfling, CM; Eccles, D; Eeles, R; Einbeigi, Z; Ejlertsen, B; EMBRACE; Engel, C; Gareth Evans, D; Feliubadalo, L; Foretova, L; Fostira, F; Foulkes, WD; Fountzilas, G; Friedman, E; Frost, D; Ganschow, P; Ganz, PA; Garber, J; Gayther, SA; GEMO Study Collaborators; Gerdes, A-M; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gronwald, J; Hahnen, E; Hamann, U; Hansen, TVO; Hart, S; Hays, JL; HEBON; Hogervorst, FBL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Jakubowska, A; James, P; Janavicius, R; Jensen, UB; John, EM; Joseph, V; Just, W; Kaczmarek, K; Karlan, BY; KConFab Investigators; Kets, CM; Kirk, J; Kriege, M; Laitman, Y; Laurent, M; Lazaro, C; Leslie, G; Lester, J; Lesueur, F; Liljegren, A; Loman, N; Loud, JT; Manoukian, S; Mariani, M; Mazoyer, S; McGuffog, L; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mulligan, AM; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nussbaum, RL; Olah, E; Olopade, OI; Ong, K-R; Oosterwijk, JC; Osorio, A; Papi, L; Park, SK; Pedersen, IS; Peissel, B; Segura, PP; Peterlongo, P; Phelan, CM; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Richardson, A; Robson, M; Rodriguez, GC; Rookus, MA; Schmutzler, RK; Sevenet, N; Shah, PD; Singer, CF; Slavin, TP; Snape, K; Sokolowska, J; Sønderstrup, IMH; Southey, M; Spurdle, AB; Stadler, Z; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Tan, Y; Tea, M-K; Teixeira, MR; Teulé, A; Teo, S-H; Terry, MB; Thomassen, M; Tihomirova, L; Tischkowitz, M; Tognazzo, S; Toland, AE; Tung, N; van den Ouweland, AMW; van der Luijt, RB; van Engelen, K; van Rensburg, EJ; Varon-Mateeva, R; Wappenschmidt, B; Wijnen, JT; Rebbeck, T; Chenevix-Trench, G; Offit, K; Couch, FJ; Nord, S; Easton, DF; Antoniou, AC; Simard, J (2017-01)
      <h4>Purpose</h4>Cis-acting regulatory SNPs resulting in differential allelic expression (DAE) may, in part, explain the underlying phenotypic variation associated with many complex diseases. To investigate whether common ...
    • Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer? 

      Bhattacharya, IS; Kirby, AM; Bliss, JM; Coles, CE (2018-03)
      Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local ...
    • Cancer heterogeneity and imaging. 

      O'Connor, JPB (2017-04)
      There is interest in identifying and quantifying tumor heterogeneity at the genomic, tissue pathology and clinical imaging scales, as this may help better understand tumor biology and may yield useful biomarkers for guiding ...
    • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 

      Adams, CD; Richmond, R; Ferreira, DLS; Spiller, W; Tan, V; Zheng, J; Würtz, P; Donovan, J; Hamdy, F; Neal, D; Lane, JA; Smith, GD; Relton, C; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Olama, AAA; Benlloch, S; Muir, K; Berndt, SI; Conti, DV; Wiklund, F; Chanock, SJ; Gapstur, S; Stevens, VL; Tangen, CM; Batra, J; Clements, JA; Gronberg, H; Pashayan, N; Schleutker, J; Albanes, D; Wolk, A; West, CML; Mucci, LA; Cancel-Tassin, G; Koutros, S; Sorensen, KD; Maehle, L; Travis, RC; Hamilton, RJ; Ingles, SA; Rosenstein, BS; Lu, Y-J; Giles, GG; Kibel, AS; Vega, A; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Brenner, H; Maier, C; Kim, J; John, EM; Teixeira, MR; Neuhausen, SL; De Ruyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, RP; Usmani, N; Claessens, F; Townsend, PA; Dominguez, MG; Roobol, MJ; Menegaux, F; Khaw, K-T; Cannon-Albright, LA; Pandha, H; Thibodeau, SN; Martin, RM; PRACTICAL consortium (2019-01)
      <h4>Background</h4>Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and ...
    • Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. 

      Tan, MP; Attard, G; Huddart, RA (2018-08-29)
      Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to ...
    • Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. 

      Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; Gonzales-de-Castro, D; O'Leary, B; Garcia-Murillas, I; Bhide, S; Hubank, M; Harrington, K; Kim, D; Newbold, K (2018-11)
      <h4>Background</h4>Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker ...
    • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 

      Scarbrough, PM; Weber, RP; Iversen, ES; Brhane, Y; Amos, CI; Kraft, P; Hung, RJ; Sellers, TA; Witte, JS; Pharoah, P; Henderson, BE; Gruber, SB; Hunter, DJ; Garber, JE; Joshi, AD; McDonnell, K; Easton, DF; Eeles, R; Kote-Jarai, Z; Muir, K; Doherty, JA; Schildkraut, JM (2016-01)
      <h4>Background</h4>DNA damage is an established mediator of carcinogenesis, although genome-wide association studies (GWAS) have identified few significant loci. This cross-cancer site, pooled analysis was performed to ...
    • Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. 

      Gilbert, DC; Al-Saadi, R; Thway, K; Chandler, I; Berney, D; Gabe, R; Stenning, SP; Sweet, J; Huddart, R; Shipley, JM (2016-03)
      <h4>Purpose</h4>Up to 50% of patients diagnosed with stage I nonseminomatous germ cell tumors (NSGCTs) harbor occult metastases. Patients are managed by surveillance with chemotherapy at relapse or adjuvant treatment up ...
    • Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. 

      Szopa, W; Burley, TA; Kramer-Marek, G; Kaspera, W (2017-01)
      Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3-5% of them survive for ...
    • Dicentric Dose Estimates for Patients Undergoing Radiotherapy in the RTGene Study to Assess Blood Dosimetric Models and the New Bayesian Method for Gradient Exposure. 

      Moquet, J; Higueras, M; Donovan, E; Boyle, S; Barnard, S; Bricknell, C; Sun, M; Gothard, L; O'Brien, G; Cruz-Garcia, L; Badie, C; Ainsbury, E; Somaiah, N (2018-12)
      The RTGene study was focused on the development and validation of new transcriptional biomarkers for prediction of individual radiotherapy patient responses to ionizing radiation. In parallel, for validation purposes, this ...
    • Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. 

      Perez-Lopez, R; Mateo, J; Mossop, H; Blackledge, MD; Collins, DJ; Rata, M; Morgan, VA; Macdonald, A; Sandhu, S; Lorente, D; Rescigno, P; Zafeiriou, Z; Bianchini, D; Porta, N; Hall, E; Leach, MO; de Bono, JS; Koh, D-M; Tunariu, N (2017-04)
      Purpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials ...
    • Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. 

      Winfield, JM; Wakefield, JC; Dolling, D; Hall, M; Freeman, S; Brenton, JD; Lutchman-Singh, K; Pace, E; Priest, AN; Quest, RA; Taylor, NJ; Gabra, H; McKnight, L; Collins, DJ; Banerjee, S; Hall, E; deSouza, NM (2019-11)
      Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. ...
    • Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? 

      O'Connor, JPB; Jayson, GC (2012-12)
      The management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, ...
    • Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. 

      Mahmood, RD; Shaw, D; Descamps, T; Zhou, C; Morgan, RD; Mullamitha, S; Saunders, M; Mescallado, N; Backen, A; Morris, K; Little, RA; Cheung, S; Watson, Y; O'Connor, JPB; Jackson, A; Parker, GJM; Dive, C; Jayson, GC
      <h4>Background</h4>Patients with metastatic colorectal cancer are treated with cytotoxic chemotherapy supplemented by molecularly targeted therapies. There is a critical need to define biomarkers that can optimise the use ...
    • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. 

      Van Cutsem, E; Cervantes, A; Adam, R; Sobrero, A; Van Krieken, JH; Aderka, D; Aranda Aguilar, E; Bardelli, A; Benson, A; Bodoky, G; Ciardiello, F; D'Hoore, A; Diaz-Rubio, E; Douillard, J-Y; Ducreux, M; Falcone, A; Grothey, A; Gruenberger, T; Haustermans, K; Heinemann, V; Hoff, P; Köhne, C-H; Labianca, R; Laurent-Puig, P; Ma, B; Maughan, T; Muro, K; Normanno, N; Österlund, P; Oyen, WJG; Papamichael, D; Pentheroudakis, G; Pfeiffer, P; Price, TJ; Punt, C; Ricke, J; Roth, A; Salazar, R; Scheithauer, W; Schmoll, HJ; Tabernero, J; Taïeb, J; Tejpar, S; Wasan, H; Yoshino, T; Zaanan, A; Arnold, D (2016-08)
      Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved ...
    • Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. 

      Payne, GS; Schmidt, M; Morgan, VA; Giles, S; Bridges, J; Ind, T; DeSouza, NM (2010-02)
      <h4>Objective</h4>To establish whether ADC and total choline were significantly different between cervical tumors with different histological characteristics (type, degree of differentiation, presence or absence of ...